deltatrials
Completed PHASE2 NCT00048204

A Study Of A New Medicine (GW597599B) For The Treatment Of Major Depressive Disorder

An 8-Week, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Fixed-Dose Study Comparing the Efficacy and Safety of GW597599B or Paroxetine to Placebo in Moderately to Severely Depressed Patients With Major Depressive Disorder

Sponsor: GlaxoSmithKline

Conditions Depressive Disorder, Major
Interventions GW597599B paroxetine
Updated 6 times since 2017 Last updated: Oct 5, 2017 Started: Nov 4, 2002 Primary completion: Sep 30, 2003 Completion: Sep 30, 2003

This PHASE2 trial investigates Depressive Disorder, Major and is currently completed. GlaxoSmithKline leads this study, which shows 6 recorded versions since 2002 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Change History

6 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  3. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE2

  4. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE2

  5. Oct 2017 — Jun 2018 [monthly]

    Completed PHASE2

▶ Show 1 earlier version

  1. Jan 2017 — Oct 2017 [monthly]

    Completed PHASE2

    First recorded

Nov 2002

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • GlaxoSmithKline
Data source: GlaxoSmithKline

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.